Seeking Alpha

Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases

AUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (PSTV) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics ...
Nasdaq

Plus Therapeutics Completes ReSPECT-LM Phase 1 Trial, Establishes RP2D for Rhenium (186Re) Obisbemeda in Leptomeningeal Metastases

Plus Therapeutics, Inc. has announced the successful completion of the ReSPECT-LM Phase 1 trial, which evaluated the safety and efficacy of intrathecally administered Rhenium (186Re) Obisbemeda for ...
Seeking Alpha

Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases

HOUSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (PSTV) (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced ...